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Background: Behçet disease (BD) is associated with a prothrombotic state of unknown origin that may lead to
life-threatening events. Calibrated Automated Thrombogram (CAT) and Rotational Thromboelastometry (ROTEM)
are two global haemostasis assays that may reveal new insights into the physiopathological mechanisms of the
disease and its procoagulant condition.
Methods: 23 BD patients who had no signs or symptoms of current thrombosis and 33 age- and sex-matched
controls were included in the study. We performed ROTEM and CAT tests and assessed erythrocyte count, platelet
count, platelet contribution to clot formation and plasma levels of tissue-type plasminogen activator, plasminogen
activator inhibitor type 1 (PAI-1), fibrinogen, C-reactive protein (CRP), thrombin-antithrombin III complex (TAT),
D-dimer and E-selectin (ES).
Results: Both ROTEM and CAT tests showed a hypercoagulable state in the BD patients. Plasma levels of PAI-1,
fibrinogen, TAT, CRP and ES were significantly increased in this group compared to controls. The disease activity
(DA) was significantly correlated with levels of ES and the maximum clot firmness, and this last one, in turn,
correlated with rising levels of ES, PAI-1, CRP and fibrinogen. CAT parameters did not correlate with DA or ES.
Conclusions: Both ROTEM and CAT tests reveal that patients with BD have a procoagulant state even in the
absence of thrombosis. ROTEM test indicates that increased levels of fibrinogen and PAI-1 may be involved in the
prothrombotic state of this pathology, while platelets do not significantly contribute. Moreover, CAT assay
demonstrate that plasma from BD patients is able to generate more thrombin than controls in response to the
same stimulus and that this effect is independent of the DA and the endothelial impairment suggesting the
involvement of another factor in the hypercoagulable state observed in BD patients. This study also shows that
endothelium activation/damage may be a contributing factor in both the procoagulant and clinical conditions of
BD, as shown by the direct correlation between ES levels, ROTEM parameters and DA.
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Behçet’s disease (BD), also known as Adamantiades–
Behçet's disease, is a rare multisystem, inflammatory disease
of unknown aetiology [1] and is associated with thrombo-
genicity [2]. Gender distribution and clinical expression of
BD varies with ethnic origin and seems to depend on the
geographic area of the BD patients’ residence [3].
The diagnosis of BD is primarily based on clinical
manifestations. New international criteria [3] have re-
cently been published as diagnostic criteria for BD and
include vascular manifestations, which is of great im-
portance due to the frequency of serious vascular and
large vessel involvement as has been recently reported
[4]. However, patients who were diagnosed according to
the International Study Group Criteria (1990) [5] also
meet the new International Criteria (2013).
The pathogenesis of the prothrombotic state in BD is
not known, although associated vascular damage/activa-
tion seems to be an important key factor [6,7]. Increased
levels of several procoagulant markers [6,8], defective fi-
brinolysis [8-11], and altered platelet function [12,13]
are some of the numerous findings that have been
obtained to date; however, these variables have been in-
vestigated individually using various methods and, in
some cases, have led to conflicting results.
In recent years, there has been growing interest in the
use of global coagulation tests in the evaluation of blee-
ding diathesis and the hypercoagulable state. Rotatio-
nal thromboelastometry (ROTEM) is a viscoelastometric
clotting test that measures the kinetics of clot formation
and fibrinolysis, providing global information on the cel-
lular and soluble procoagulant/anticoagulant protein in-
teractions. Calibrated automated thrombogram (CAT) is
a thrombin generation test developed by Hemker et al.
[14] that quantifies thrombin generation beyond the end
points of traditional coagulation tests. Both techniques
have been applied successfully to the study of the pro-
coagulant state associated with various conditions, in-
cluding inflammatory states [15-17].
Considering that haemostasis emerges from the inter-
play between different cells, coagulation factors and inhib-
itors, these global tests may reveal a better understanding
of the hypercoagulable condition in BD than has been
obtained so far through subrogated and isolated procoagu-
lant markers. Therefore, we investigated the potential util-
ity of ROTEM and CAT in the characterisation of the
procoagulant state in BD and assessed whether these tests
offer a new insight into the physiopathological mecha-
nisms of the disease and its procoagulant profile.
Methods
Study design and subjects
This was a case–control study. Patients diagnosed with
BD, according to the criteria of the International StudyGroup for Behçet’s Disease [5], who were over 18 years
of age and who attended the Rheumatology Unit of
the Gregorio Marañón University Hospital were in-
vited to participate in the study. The activity index
was determined as described by the Bhakta et al.
guidelines [18]. Healthy blood donors from the blood do-
nation centre of the La Paz University Hospital were in-
cluded as controls. The hospital ethic committee
approved the experimental protocol, and subjects were in-
cluded after signing the informed consent. Exclusion cri-
teria were smoking, the use of oral contraceptives,
anticoagulant or active antiplatelet drugs, uncontrolled
hypertension, diabetes, hyperlipidaemia, peripheral or
coronary artery disease, the presence of abnormal hepatic
or renal function, antiphospholipid antibodies (anti-
cardiolipin, anti-beta2-glycoprotein I and lupus anticoagu-
lant) and lupus.Collection and handling of samples
To avoid the influence of circadian changes in the
study variables, the collection time was the same for
all subjects (between 9 A.M. and 10 A.M.). Peripheral
blood was collected in ethylenediaminetetraacetic acid
tubes (Becton, Dickinson and Company, Madrid,
Spain) for blood cell count and in sodium citrate
(1.3%) tubes (Becton, Dickinson and Company,
Madrid, Spain) for the remaining tests. Citrated whole
blood was centrifuged at 2500 g for 20 min at 23°C to
obtain platelet poor plasma (PPP). PPP aliquots were
stored immediately at −70°C until analysis. All sam-
ples were analysed or stored properly within two
hours of sampling.Calibrated Automated Thrombogram (CAT)
Thrombin generation was measured in PPP by CAT as
described previously [14]. All measurements were
performed after 10 minutes of preheating at 37°C. Co-
agulation was triggered by proper recalcification and
the addition (final concentrations) of 1 pM of recom-
binant human tissue factor and 4 μM of phospholipid
mixture (PPP-Reagent LOW, Thrombinoscope BV,
Maastricht, The Netherlands). Lag time (LT, time re-
quired for the formation of 10 nM thrombin), time-to-
peak (TTP, time required to reach the maximum
thrombin concentration), peak height (PH, maximum
thrombin concentration achieved), and endogenous
thrombin potential (ETP, area under the thrombin con-
centration vs. time curve) were calculated with the
Thrombinoscope software package (Thrombinoscope
BV, Maastricht, The Netherlands). The velocity index
(VI), a parameter related to the speed with which
thrombin is produced, was calculated from the experi-
mental data as follows:
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TTP−LTð Þ
Rotational Thromboelastometry (ROTEM)
ROTEM was performed on whole blood that was
allowed to rest at room temperature for 30 min before
testing. A partial thromboplastin phospholipid and el-
lagic acid-activated intrinsic pathway (INTEM test) was
performed to assess the kinetics of clot formation. We
recorded the clot formation time (INTEM-CFT, time to
20-mm amplitude [in seconds], which reflects the speed
of the clotting process), alpha angle (INTEM-α, tangent
to the curve at 2-mm amplitude [in degrees], which re-
flects the rate of fibrin polymerisation), and maximum
clot firmness (INTEM-MCF, maximum clot firmness [in
mm], which reflects the maximum tensile strength of
the thrombus). To assess the contribution of platelets to
the clot kinetics, a platelet-inhibited FIBTEM test was
performed and compared with the INTEM test for MCF
using the following formula:
Platelet contribution MCFð Þ
¼ INTEM MCFð Þ−FIBTEM MCFð Þ½ 
INTEM MCFð Þ  100
Cell count, biochemistry and study of fibrinolysis
The blood cell count was performed with a Coulter Ac
T Diff cell counter (Beckman Coulter, Madrid, Spain).
Plasma levels of D-dimer (DD) and fibrinogen were de-
termined using a BCS© XP system (Siemens Healthcare
Diagnostics Products GmbH, Marburg, Germany) and
C-reactive protein (CRP) was measured by nephelomet-
ric method (Behring Nephelometer Analyzer, Germany).
Thrombin-antithrombin III complex (TAT) (AssayMax
Human Thrombin-antithrombin Complexes ELISA Kit,
ASSAYPRO, St. Charles, MO, USA) and E-selectin (ES)
(Human sE-Selectin/CD26E Immunoassay Quantikine©
ELISA kit, R&D Systems Europe Ltd., Abingdon, UK)
were measured in PPP, following the manufacturer’s in-
structions. The fibrinolytic profile was evaluated by
assessing plasma antigenic levels of tissue-type plas-
minogen activator (t-PA) (TriniLIZE tPA antigen ELISA
kit) and plasminogen activator inhibitor type 1 (PAI-1)
(TriniLIZE PAI-1 antigen ELISA kit); all kits were ac-
quired from Trinity Biotech, Bray, Co Wicklow, Ireland.
Statistical analysis
The results are expressed as the mean ± SD, the median
and range (25th-75th percentile) or as the absolute value
(percentage of the total). We performed an unpaired
Student's t-test and the Mann–Whitney U test as needed
to compare variables between the groups. The asso-ciations between the variables were calculated using
Pearson’s or Spearman's correlation test, depending on
the data distribution. Normality was tested by a Shapiro-
Wilk test. Statistical analyses were performed using SPSS
software version 17.0 for Windows (SPSS, Chicago, IL,
USA). Values of P ≤ 0.05 were considered statistically
significant.
Results
Of the 33 unrelated BD patients interviewed, 23 were in-
cluded and compared with 33 age and gender matched
healthy subjects. Ten patients were excluded because
they did not fulfil inclusion criteria. None of the
interviewed patients had signs or symptoms of current
thrombosis. The clinical and treatment characteristics of
the patients are summarised in Table 1.
Cell count, biochemistry and study of fibrinolysis
We found significantly increased levels of fibrinogen,
CRP, PAI-1 antigen, TAT and ES in the BD patients
(Table 2). There were no significant differences in the
other variables between the groups (Table 2).
Rotational Thromboelastometry (ROTEM)
The coagulation profiles assessed by the ROTEM test
showed enhanced coagulation in patients with BD. The
clot formation speed (evaluated by INTEM-α and
INTEM-CFT) and the INTEM-MCF were significantly
higher in this group (Table 2). INTEM-MCF showed
correlations with fibrinogen levels in both patients and
controls (patients: r = 0.620, p = 0.005; controls: r =
0.638, p = 0.002) and with CRP in the BD group (r =
0.384, p = 0.02). INTEM-MCF, INTEM-α and INTEM-
CFT were affected by the levels of PAI-1 (INTEM-MCF:
r = 0.648, p = 0.012; INTEM-α: r = 0.650, p = 0.012 and
INTEM-CFT: r = −0.690, p = 0.006) in the BD patients.
In controls, INTEM-CFT correlated with the levels of
PAI-1 (r = 0.645, p = 0.044). The calculated percentage of
platelet contribution to INTEM-MCF was similar in
both groups, suggesting a poor contribution of platelets
to the procoagulant state observed by thromboelas-
tometry in the BD patients (Table 2).
Calibrated Automated Thrombogram (CAT)
LT, PH, ETP and VI were significantly increased in pa-
tients with BD (Table 2). In this group, the levels of fi-
brinogen correlated with LT (r = 0.622, p = 0.004), TTP
(r = 0.548, p = 0.015) and ETP (r = 0.452, p = 0.05). We
found a moderate negative correlation between LT and
INTEM-CFT (r = −0.568, p = 0.007) and a moderate
positive correlation between LT and INTEM-α (r =
0.536, p = 0.012). This provided compelling evidence that
the increased thrombus formation in BD patients was
associated with a delay in the start of thrombin gene-
Table 1 Clinical features and treatment of BD patients at
the time of the study and cumulative
Characteristic At time of the
study
Cumulative
Clinical features: N = 23
Disease duration in years
(mean ± SD)
15 ± 8 -
Deep vein thrombosis (%) 0 4
Disease activity, median (p25-p75) 7 (2–18) -
Patients on active phase of
disease (%)
78 -
Genital ulcer (%) 13 97
Oral ulcer (%) 52 100
Skin lesion (%) 43 90
Vascular involvement (%) 0 21
Articular involvement (%) 43 67
Gastrointestinal involvement (%) 30 32
Ocular involvement (%) 22 64
Neurological involvement (%) 43 72
Treatments:
Prednisone (< 10 mg) (%) 9 83
Prednisone (> 10 mg) (%) 18 87
Cyclosporine (%) 4 18
Azathioprine (%) 9 32
Methotrexate (%) 4 7
Infliximab (%) 4 3
Rituximab (%) 4 7
Colchicine (%) 17 86
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dependence between PH and the rate of fibrin polymer-
isation (INTEM-α: r = 0.432, p = 0.05), which suggests
that the increase in the clot formation speed might be
related with the higher thrombin generation capacity in
this group.Relationship between DA, coagulation status and
endothelial cell injury/activation
We observed correlations between DA and INTEM-
MCF, INTEM-α and ES levels (Figure 1), indicating that
increased DA was associated with a higher thrombus
formation capacity and more severe vascular injury/acti-
vation. In turn, the ES levels correlated with INTEM-
CFT, INTEM-MCF and INTEM-α (Figure 2), suggesting
a possible relationship between endothelial cell injury/
activation and the hypercoagulable state observed by the
ROTEM test in the BD patients. Except for the fibrino-
gen and INTEM-MCF, there were no correlations be-
tween ROTEM parameters and the other variables in
the control group.We also observed a significant correlation between
antigenic levels of PAI-1 and DA (r = 0.739, p = 0.009)
and ES levels (r = 0.640, p = 0.034) in patients with active
disease (DA > 0), which implicates PAI-1 as a potential
link between vasculitis and/or the inflammatory state
and enhanced clot formation in BD patients. The CAT
parameters failed to correlate with ES levels and DA in
the BD patients.
Discussion
As far as we know, this is the first report on the use of
ROTEM and CAT in the study of the procoagulant state
in BD. The present study has shown that thrombin gen-
eration and blood clotting capacity were increased in BD
patients, even in the absence of thrombosis. Additio-
nally, we found significant correlations between the
ROTEM parameters, plasma ES levels and DA, which
suggests links between the procoagulant state, endo-
thelial inflammation and severity of symptoms of the
disease.
We found increased levels of fibrinogen in our group
of patients with BD. This result is consistent with those
observed in previous studies [19-21] and is not surpri-
sing considering that 78% of our patients were in an ac-
tive state and that fibrinogen is an acute phase reactant
[22]. The procoagulant effect of fibrinogen on ROTEM
parameters has been reported previously [23], and our
results are in agreement with this effect. We observed
that fibrinogen levels were significantly correlated with
INTEM-MCF in both patients and controls, which sug-
gests that increased levels of fibrinogen in the BD group
might be involved in the group’s hypercoagulable profile,
as determined by the ROTEM test. Surprisingly, al-
though INTEM-MCF correlated significantly with the
fibrinogen levels and DA, we did not observe any de-
pendence between the fibrinogen levels and DA. This
issue, which was also observed by Hampton et al. [19],
is intriguing but may be the result of the high variability
of the fibrinogen synthesis route due to alternative
mRNA processing, post-translational modifications and
proteolytic degradation, which may lead to different
levels of fibrinogen in response to similar inflammatory
states [24]. Fibrinogen may also affect thrombin gene-
ration. Dielis et al. have shown that fibrinogen may pro-
duce not only an anticoagulant effect by increasing LT
but also a procoagulant effect by heightening ETP and
PH values in normal populations [25]. This dual anti-
coagulant/procoagulant effect can be explained by the
spatial distribution of the thrombin’s binding sites and
the kinetics of interaction with its multiple substrates.
Increased fibrinogen levels may prolong LT because of
this molecule’s ability to bind to thrombin through
exosite II, which is needed for the thrombin-mediated
FVIII activation. This fibrinogen binding leads to an
Table 2 Demographic features, ROTEM and CAT results of both groups
Characteristics BD patients (N = 23) Controls (N = 33) p-value
Age at inclusion (year) 49 ± 15 43 ± 10 0.082
Female gender (%) 78 63 0.241
INTEM-α (degree) 77 ± 3 74 ± 2 <0.010
ROTEM INTEM-CFT (sec) 66 ± 15 80 ± 14 <0.010
INTEM-MCF (mm) 61 ± 4 57 ± 4 <0.010
Platelet contribution-MCF (%) 78 (69–79) 79 (77–81) 0.090
Lag-time (min) 6.7 ± 1.8 5.6 ± 1.1 0.025
CAT
Time-to-peak (min) 9.6 ± 1.9 9.0 ± 1.4 0.240
Peak height (nM) 292 ± 65 213 ± 67 <0.010
ETP (nM ×min) 1543 ± 331 1286 ± 292 0.010
Velocity index (nM/min) 102 (83–127) 55 (42–90) <0.010
Platelet count (×103/μl) 217 (189–287) 227 (199–247) 0.785
Erythrocyte count (×106/μl) 4.2 ± 0.4 4.3 ± 0.4 0.244
Fibrinogen (mg/l) 321 ± 53 280 ± 42 <0.010
TAT (ng/l) 19 (17–21) 15 (12–17) <0.010
Other parameters D-dimer (μg/l) 293 ± 65 270 ± 86 0.480
tPA (antigen) (ng/ml) 17.2 ± 7.2 12.4 ± 5.2 0.120
PAI-1 (antigen) (ng/ml) 19.9 ± 8.6 12.6 ± 6.0 0.032
E-selectin (μg/l) 24.2 ± 9.3 16.8 ± 8.4 0.040
C-reactive protein (mg/dl) 0.2 (0.1-0.5) 0.1 (0.1-0.4) 0.046
Results are expressed as the mean ± SD, the median and range (25th-75th percentile) or as absolute value (%).
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factor concentrations [26,27]. This evidence has also
been supported by Hemker et al. who compared throm-
bin generation in full and defibrinated plasma [28]. It is
interesting to mention that a prolonged LT despite an
increased thrombotic risk is observed in patients with
antiphospholipid syndrome [29] which suggests that an
extended LT does not rule out the presence of a
prothrombotic state. Fibrinogen may also increase
thrombin generation due to fibrin’s ability to protect
thrombin from inhibition by antithrombin III [28,30].
Our results agree with these hypotheses, given that we
found a significant positive correlation between fibri-
nogen levels and ETP in patients with BD. In summary,
although fibrinogen could induce an anticoagulant ef-Figure 1 Correlation between disease activity (DA) and INTEM-MCF, Ifect by increasing the LT for generating thrombin, the
amount of thrombin generated (ETP) and the strength
of the clot (INTEM-MCF) were increased by higher
levels of fibrinogen in the BD group. This condition
could be responsible, at least in part, for the procoagu-
lant pattern observed in the BD patients by the two glo-
bal tests.
Previous studies have reported a correlation between
platelet count (PTS) and clot formation speed and
strength [31]. However, we did not find any differences
in PTS between the patients and the controls. Although
higher platelet activation and response to stimulus have
been reported in BD patients [13,32], our research group
recently published a study of platelet function in the
same group of BD patients included in the present studyNTEM-α and soluble E-selectin (ES).
Figure 2 Correlation between soluble E-selectin (ES) and INTEM-CFT, INTEM-MCF and INTEM-α.
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between the controls and the BD patients, either at base-
line conditions or after stimulation with agonists (TRAP
and ADP) [33]. After considering this finding and the
lack of differences in PTS and platelet contribution to
the ROTEM trace between the groups, we conclude that
platelets are not the cause of the deviation in the
ROTEM results.
A study by Spiezia et al. (2008) suggests that erythro-
cyte count (ERY) may decrease clot firmness [34]. In the
present study, we did not observe any significant differ-
ences in the ERY between the patients and controls, and
therefore the contribution of ERY to the differences ob-
served in the ROTEM trace between the two groups
seems negligible.
It has been reported that abnormal fibrinolysis may
contribute to thrombosis, atherosclerosis and vascular
stenosis [35]. Fibrinolysis has been previously studied in
BD with conflicting results, which was probably due to
the high variability of patients included in the stu-
dies and the different assays used in each case
[8-10,19,36-38]. In the present study, BD patients
showed tPA antigen levels similar to controls but had
significantly increased PAI-1 antigen plasma levels,
suggesting a possible hypofibrinolitic profile in this
group. Systemic inflammation as presented in BD could
increase PAI-1 levels [39,40]. Moreover, it has been
reported that platelet stimulation by thrombin induces
platelet synthesis and release of active PAI-1 [41,42] and,
in fact, increased platelet activation has been highly cor-
related to plasma PAI-1 activity in acute stroke patients
[43]. Thrombin may also stimulate platelet synthesis and
secretion of TGF beta [44-46]. TGF beta, in turn, may
increase the synthesis of PAI-1 in endothelial cells
[44-46]. These mechanisms may explain, at least in part,
the increased plasma levels of PAI-1 in BD patients be-
cause they show systemic activation of coagulation and
increased thrombin production in response to stimulus.
Increased levels of PAI-1 can increase the clot formation
speed and clot stability [47,48] due to the rapid and irre-
versible blockage of the protease activity of tPA, the
main plasminogen activator [49]. Our results agree withthis observation given that we found a significant correl-
ation between antigenic levels of PAI-1 and INTEM-CFT,
INTEM-α and INTEM-MCF, which points to PAI-1 as
a key factor in the procoagulant state observed in BD
patients by this test. In spite of the fact that an associ-
ation between levels of PAI-1 and thrombosis in BD
has not been reported, relief from vascular events and
oral ulcers after treatment with profibrinolytic agents
has been observed in these patients [50,51]. Moreover,
we and other groups have observed a positive corre-
lation between PAI-1 levels and DA, suggesting a pro-
bable association between the impaired fibrinolysis in
BD and the severity of the disease symptoms [19,52].
Whether this finding reflects a causal relation between
BD symptoms and defective fibrinolysis is an issue that
needs to be evaluated in further studies with larger
numbers of patients.
The procoagulant state observed by the CAT and
ROTEM tests in the BD patients was supported by the
increase in plasma TAT, a marker of intravascular
thrombin formation. However, the TAT level did not
correlate to the ROTEM and CAT parameters. A lack of
correlation between TAT levels and CAT and ROTEM
values has been previously reported [53-55] which sug-
gests that the TAT level might indicate that activation of
coagulation had occurred but does not necessarily reflect
the patient’s procoagulant potential at the time of the
sampling.
In contrast to previous reports that indicated high DD
levels in BD patients with active disease and deep vein
thrombosis [11], we did not find any differences in DD
between the BD patients and controls. This controversial
result may be due to the absence of signs, symptoms or
recent history of thrombosis in our patients.
Endothelial damage has been described as a potential
key factor involved in the prothrombotic state of BD
[7,8], and ES, a marker of endothelial damage/activation,
has been found to be increased in the active state of the
disease [56]. Our results were in correspondence with
this data as we found higher levels of ES in the BD pa-
tients compared with controls that correlate with DA
(Figure 1). When analyzing the correlation between ES
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cant correlation between ES levels and the ROTEM pa-
rameters but not between ES levels and the CAT
parameters. We also failed to obtain any correlation bet-
ween CAT parameters and DA that by the contrary
showed correlation with the procoagulant profile ob-
served by the ROTEM test. One hypothesis to explain
this effect may be based on the fact that the CAT test is
only able to depict the thrombin generation capacity of
the plasma, whereas the ROTEM test describes throm-
bin generation, clot formation and fibrinolysis. As shown
above, these processes may be altered in this disease,
and therefore the ROTEM test may be a more appropri-
ate test for describing the associated endothelial and in-
flammatory pathological condition of the disease.
Our results support the existence of an increased pro-
coagulant state in BD patients, and they raise the question
about the usefulness of anticoagulant treatments in these
patients. This is a matter of controversy as there is no
consensus among rheumatologists from various countries
[57] because lifelong anticoagulation treatment might in-
crease the risk of fatal bleeding [58]. Moreover, given that
blood vessel wall inflammation is a possible cause of
thrombosis in BD patients, the use of immunosuppressive
therapy might be a more rational choice [59,60].
Conclusions
The ROTEM test is a useful tool for studying of hyper-
coagulable state in BD. Additionally, CAT experiments re-
veal that plasma from BD patients is able to produce
faster and higher thrombin generation. Our data also indi-
cated that endothelial activation/damage is involved in
both the clinical manifestation and procoagulant state of
this pathology. Moreover, the heightening of fibrinogen
and PAI-1 may be important components in the pro-
coagulant condition of the disease, whereas the effect of
platelets seemed to be almost negligible. Further studies
are warranted to evaluate the relationship between PAI-1
levels and the symptoms of the disease and to determine
whether the ROTEM test and ES levels are useful tools/
markers for monitoring therapeutic response and disease
progression in BD patients.
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